<DOC>
	<DOCNO>NCT02088216</DOCNO>
	<brief_summary>Objective : To evaluate whether long-term oral N-acetylcysteine expectorant drug reduce frequency acute exacerbation patient non-cystic fibrosis bronchiectasis improve quality life . Methods : Patients non-cystic fibrosis bronchiectasis randomly assign observer group ( participant receive 600 mg oral N-acetylcysteine BID 12 month ) control group ( participant receive oral tablet BID 12 month ) . The primary endpoint frequency acute exacerbation . Expected result : Compared control group , frequency acute exacerbation observer Group decrease significantly . Hypothesis : Long-term oral N-acetylcysteine reduce frequency acute exacerbation patient non-cystic fibrosis bronchiectasis improve quality life .</brief_summary>
	<brief_title>Effect Long-term , High-dose N-acetylcysteine Exacerbations Bronchiectaisis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Bronchiectasis</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>Male female study subject ≥18 year age ≤80 year age ; Confirmed diagnosis idiopathic bronchiectasis postinfectious bronchiectasis Stable Bronchiectasis One month later acute exacerbation bronchiectasis There 2 time exacerbation bronchiectasis one year enrollment . Bronchiectasis due special cause Smokers Are associate bronchial asthma Have serious active medical psychiatric illness .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>N-acetylcysteine；</keyword>
	<keyword>Bronchiectasis；</keyword>
	<keyword>Acute exacerbations；</keyword>
	<keyword>Antioxidant；</keyword>
	<keyword>Anti-inflammatory</keyword>
</DOC>